Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Given Average Recommendation of “Moderate Buy” by Brokerages

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has been assigned a consensus recommendation of “Moderate Buy” from the seven research firms that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating and six have issued a buy rating on the company. The average 1 year price objective among brokers that have covered the stock in the last year is $14.8333.

KPTI has been the topic of several analyst reports. Piper Sandler reiterated an “overweight” rating and issued a $12.00 target price on shares of Karyopharm Therapeutics in a report on Wednesday, December 17th. Royal Bank Of Canada decreased their target price on Karyopharm Therapeutics from $30.00 to $19.00 and set an “outperform” rating for the company in a research report on Tuesday, November 4th. Cantor Fitzgerald assumed coverage on shares of Karyopharm Therapeutics in a research note on Thursday, February 5th. They issued an “overweight” rating on the stock. Wall Street Zen upgraded shares of Karyopharm Therapeutics from a “strong sell” rating to a “hold” rating in a report on Saturday, November 8th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Karyopharm Therapeutics in a research report on Monday, December 29th.

Karyopharm Therapeutics Stock Performance

Shares of Karyopharm Therapeutics stock opened at $7.37 on Thursday. The stock has a market cap of $134.94 million, a PE ratio of -0.51 and a beta of 0.21. Karyopharm Therapeutics has a 52-week low of $3.51 and a 52-week high of $10.38. The firm has a 50-day moving average of $6.86 and a 200-day moving average of $6.18.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings results on Thursday, February 12th. The company reported ($5.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.26) by ($3.45). The company had revenue of $34.08 million for the quarter, compared to analyst estimates of $33.16 million. Equities research analysts predict that Karyopharm Therapeutics will post -0.71 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Baird Financial Group Inc. bought a new position in Karyopharm Therapeutics during the second quarter worth about $45,000. XTX Topco Ltd bought a new stake in shares of Karyopharm Therapeutics during the 2nd quarter valued at $56,000. Bridgeway Capital Management LLC purchased a new stake in Karyopharm Therapeutics during the 2nd quarter worth about $163,000. ADAR1 Capital Management LLC purchased a new stake in shares of Karyopharm Therapeutics in the third quarter worth about $164,000. Finally, Silverback Asset Management LLC lifted its stake in Karyopharm Therapeutics by 40.0% in the 2nd quarter. Silverback Asset Management LLC now owns 70,000 shares of the company’s stock worth $302,000 after purchasing an additional 20,000 shares in the last quarter. Institutional investors own 66.44% of the company’s stock.

About Karyopharm Therapeutics

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.